MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ
1.120
-0.020
-1.75%
After Hours: 1.150 +0.03 +2.68% 19:40 11/13 EST
OPEN
1.150
PREV CLOSE
1.140
HIGH
1.150
LOW
1.080
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
2.855
52 WEEK LOW
1.080
MARKET CAP
200.79M
P/E (TTM)
-1.7516
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Palisade Bio (PALI), Medios AG (MEDOF)
TipRanks · 1d ago
Palisade Bio’s Strong Cash Position and Promising PALI-2108 Pipeline Support a Bullish Outlook
TipRanks · 1d ago
Palisade Bio Analysts Slash Their Forecasts After Q3 Results
Benzinga · 3d ago
Palisade Bio Price Target Cut to $16.00/Share From $25.00 by Piper Sandler
Dow Jones · 3d ago
Palisade Bio Is Maintained at Overweight by Piper Sandler
Dow Jones · 3d ago
Piper Sandler Maintains Overweight on Palisade Bio, Lowers Price Target to $16
Benzinga · 3d ago
Palisade Bio price target lowered to $16 from $25 at Piper Sandler
TipRanks · 3d ago
Analysts’ Top Healthcare Picks: Myomo (MYO), Palisade Bio (PALI)
TipRanks · 3d ago
More
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

Webull offers Palisade Bio Inc stock information, including NASDAQ: PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.